8 in 8: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLC

In this video in the 8 in 8 Series, Dr. Dwight Owen (Ohio State University) discussed advances in biomarker testing and neoadjuvant immunotherapy for resectable non-small cell lung cancer. The talk includes a look at the role of PD-L1 testing, peri-operative chemo-immunotherapy, and the importance of NGS testing for patients with actionable mutations.

Supported by AstraZeneca.

The Society’s 8 in 8 Series offers quick access to important topics in cardiothoracic surgery. Each informative video is narrated by an expert in the field and covers one topic using eight slides in 8 minutes. No CME credit is associated with the viewing of web-based content. STS retains sole rights to these materials.